Mesh.i
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Serveur d'exploration Tocilizumab - Exploration (Accueil)

Index « Mesh.i » - entrée « Drug Approval »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Drug Administration Schedule < Drug Approval < Drug Carriers  Facettes :

List of bibliographic references indexed by Drug Approval

Number of relevant bibliographic references: 14.
Ident.Authors (with country if any)Title
001127 (2018) Nicolai Leuchten [Allemagne] ; Martin Aringer [Allemagne]Tocilizumab in the treatment of giant cell arteritis.
001166 (2018) Ali Berkant Avci [Turquie] ; Eugen Feist [Allemagne] ; Gerd Rüdiger Burmester [Allemagne]Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
001480 (2018) Takayuki Yamamoto [États-Unis] ; Qi Li [République populaire de Chine] ; Hidetaka Hara [États-Unis] ; Liaoran Wang [République populaire de Chine] ; Hongmin Zhou [République populaire de Chine] ; Juan Li [République populaire de Chine] ; Devin E. Eckhoff [États-Unis] ; A. Joseph Tector [États-Unis] ; Edwin C. Klein [États-Unis] ; Ray Lovingood [États-Unis] ; Mohamed Ezzelarab [États-Unis] ; David Ayares [États-Unis] ; Yi Wang [République populaire de Chine] ; David K C. Cooper [États-Unis] ; Hayato Iwase [États-Unis]B cell phenotypes in baboons with pig artery patch grafts receiving conventional immunosuppressive therapy.
001481 (2018) Axicabtagene ciloleucel (Yescarta) for B-cell lymphoma.
001616 (2017) Martin Sheppard [Royaume-Uni] ; Faidra Laskou [Royaume-Uni] ; Philip P. Stapleton [Royaume-Uni] ; Shahryar Hadavi [Royaume-Uni] ; Bhaskar Dasgupta [Royaume-Uni]Tocilizumab (Actemra).
001820 (2017) Tetsuya Akaishi [Japon] ; Ichiro Nakashima [Japon]Efficiency of antibody therapy in demyelinating diseases.
001B01 (2016) M. Philippart [Pays-Bas] ; J. Schmidt [Suisse] ; B. Bittner [Suisse]Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens.
002090 (2015) David Ternant [France] ; Theodora Bejan-Angoulvant [France] ; Christophe Passot [France] ; Denis Mulleman [France] ; Gilles Paintaud [France]Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
003492 (2012) Janice M. ReichertMarketed therapeutic antibodies compendium
003C21 (2010) Tocilizumab (Actemra) for rheumatoid arthritis.
003C58 (2010) Cheryl A. ThompsonFDA approves tocilizumab to treat rheumatoid arthritis.
004057 (2008) Norihiro Nishimoto[IL-6 inhibitors for treatment of rheumatoid arthritis].
004067 (2008) Yoshiyuki Ohsugi [Japon] ; Tadamitsu KishimotoThe recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.
004379 (????) Janice M. ReichertLetter from the editor.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Drug Approval" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Drug Approval" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Drug Approval
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021